Trump’s administration continues its push to reduce US drug costs, targeting disparities with other wealthy nations, as new ...
After 27 years in business, Cytokinetics hopes to pit its own cardiac myosin inhibitor against one it initially developed—now owned by Bristol Myers Squibb—in a market worth billions. Aficamten has a ...
In this study, researchers aimed to determine whether Ki67 and TILs in residual breast tumors were prognostic for survival in patients with triple-negative breast cancer who received neoadjuvant ...
Japanese biotech Nxera Pharma (TSE: 4565) has revealed that Germany’s Boehringer Ingelheim opted not to exercise its ...
US radioisotope producer Niowave has expanded its supply agreement with British pharma AstraZeneca (LSE: AZN) to a 10-year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback